GW9662 NEW
| Price | $47 | $47 | $57 | $57 | $92 | $92 |
| Package | 5mg | 5mg | 10mg | 10mg | 25mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: GW9662 | CAS No.: 22978-25-2 |
| Purity: 99.98% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | GW9662 |
| Description | GW9662 (TIMTEC-BB SBB006523) is a PPARγ antagonist (IC50=3.3 nM) with selectivity. GW9662 can be used to study the pathogenesis of metabolic diseases, such as obesity and diabetes, by inhibiting the activity of PPARγ. GW9662 can be used to study the pathogenesis of inflammatory diseases, such as atherosclerosis and rheumatoid arthritis. GW9662 has anti-tumor effect. |
| Cell Research | MDA-MB-231 cells are seeded at a density of 1 × 105 cells per 25 cm3 tissue culture flask. After 24 h (day 0), the growth medium is replaced with fresh medium containing rosiglitazone (50 μM), GW9662 (10 μM) or both together. Control flasks receives 0.1% DMSO. Cells are harvested on days 0, 3, 5, 7, 10 for each treatment condition by trypsinisation, stained using trypan blue, and the total and viable number of cells per flask calculates using a haemocytometer.(Only for Reference) |
| Kinase Assay | Binding assay: The human PPARα, PPARγ, and PPARδ ligand binding domains (LBDs) are expressed in E. coli as polyhistidine-tagged fusion proteins. Receptors are immobilized on SPA beads by addition of the desired receptor (15 nM) to a slurry of streptavidin-modifed SPA beads (0.5 mg/mL) in assay buffer. The mixture is allowed to equilibrate for at least 1 hour at room temperature, and the beads are pelleted by centrifugation at 1×103 g. The supernate is discarded, and the beads are resuspended in the original volume of fresh assay buffer with gentle mixing. The centrifugation/resuspension procedure is repeated, and the resulting slurry of receptor-coated beads is used immediately or stored at 4 ℃ for up to 1 week before use. [3H]GW2443 are used as radioligands for determination of competition binding to PPARα, PPARγ, and PPARδ, respectively. Unless otherwise indicated, the buffer used for all assays is 50 mM HEPES (pH 7), 50 mM NaCl, 5 mM CHAPS, 0.1 mg/mL BSA, and 10 mM DTT. For some experiments, the HEPES (pH 7) is replaced with 50 mM Tris (pH 8). |
| In vitro | METHODS: Human breast cancer cell lines (MCF7, MDA-MB-468, and MDA-MB-231) were treated with GW9662 (100 nM-50 mM) for 72 hours, and MTT assay was used to detect the inhibition of cell growth. RESULTS: GW9662 significantly inhibited the proliferation of MCF7, MDA-MB-468, and MDA-MB-231 cells (IC50= 20-30 μM). [1] |
| In vivo | METHODS: To study the blocking effect of GW9662 on the protective effect of lipopolysaccharide, first, rats were pretreated with lipopolysaccharide (1 mg/kg,i.p.), which could significantly weaken all ischemia/reperfusion injury characteristics caused by renal injury and dysfunction. Then, GW9662 (1 mg/kg) was intraperitoneally injected into the rats. RESULTS: GW9662 can block the protective effect of lipopolysaccharide.[2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 255 mg/mL (921.64 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (18.07 mM), Sonication is recommended. Ethanol : 6.9 mg/mL (24.94 mM), Heating is recommended. |
| Keywords | TIMTEC-BB SBB-006523 | TIMTEC-BB SBB 006523 | PPARδ | PPARγ | PPARα | PPAR | Peroxisome proliferator-activated receptors | Inhibitor | inhibit | GW-9662 | GW9662 |
| Inhibitors Related | PHYTOL | Rosiglitazone | Retinoic acid | Daidzein | Fenofibrate | Magnesium acetate tetrahydrate | Maltitol | Naringenin | 2,3-Butanediol | NPC 15199 | Icariin | Cloxiquine |
| Related Compound Libraries | Nuclear Receptor Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Anti-Obesity Compound Library | Inhibitor Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY